Effect of Antithyroid Drugs Treatment Duration on The Remission Rates of Graves' Disease in Children and Adolescents: A Single‐Arm Meta‐Analysis and Systematic Review
Clinical Endocrinology · 2025
DOI: 10.1111/cen.15159 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Yang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health,…. Hauptthemen laut MEDLINE: Graves Disease, Antithyroid Agents, Remission Induction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was supported by Wu Jieping Medical Foundation Special Fund for Clinical Research..
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Antithyroid drugs (ATDs) are the preferred treatment option for Graves' disease (GD), yet there is a lack of systematic evaluations studying the relationship between treatment duration and therapeutic outcomes. This study aims to assess the remission rate (RR) in children with GD under ATDs therapy and to conduct an analysis of associated factors.
Method
Systematically searched PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure and Wanfang database, with a search time limit from the establishment of the database to 23 November 2023. The primary outcome was the RR. The pooled RR was calculated and subgroup comparisons were performed. Meta‐analysis was conducted using R Studio 2023.09.0 + 463 software.
Results
The study incorporated a total of 19 research projects, which collectively involved 3359 paediatric patients diagnosed with GD (comprising 2600 girls and 759 boys). The overall RR for paediatric GD treated with ATDs was 25.4% (95% Confidence Interval [CI]: 20.7%, 30.1%). The pooled RR following treatment durations of < 2 years, 2−5 years, and > 5 years were respectively 15.5%, 24.1% and 33.0%. Meta‐regression results indicated that the duration of treatment and follow‐up duration were significant sources of high heterogeneity among the studies. Specifically, for every additional year of ATDs treatment, there was an increase in the RR by 3.8% (Coefficient = 3.8%, 95% CI: 0.6%, 7.0%, p < 0.01).
Conclusion
The overall RR for the treatment of paediatric GD with ATDs is 25.4%, and prolonging the treatment course can indeed lead to an increased RR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Department of Ultrasound, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
ORCID-Profile: Chun-Xiu Gong
Förderung
- This study was supported by Wu Jieping Medical Foundation Special Fund for Clinical Research.
Zitieren
APA
Li, Y., Wang, X. M., Shi, W. Y., Chen, J. J., Song, Y. N., & Gong, C. X. (2025). Effect of Antithyroid Drugs Treatment Duration on The Remission Rates of Graves' Disease in Children and Adolescents: A Single‐Arm Meta‐Analysis and Systematic Review. Clinical Endocrinology. https://doi.org/10.1111/cen.15159
Vancouver
Li Y, Wang XM, Shi WY, Chen JJ, Song YN, Gong CX. Effect of Antithyroid Drugs Treatment Duration on The Remission Rates of Graves' Disease in Children and Adolescents: A Single‐Arm Meta‐Analysis and Systematic Review. Clinical Endocrinology. 2025. doi:10.1111/cen.15159
BibTeX
@article{Li2025,
author = {Li, Yang and Wang, Xin-Meng and Shi, Wen-Yuan and Chen, Jia-Jia and Song, Yan-Ning and Gong, Chun-Xiu},
title = {Effect of Antithyroid Drugs Treatment Duration on The Remission Rates of Graves' Disease in Children and Adolescents: A Single‐Arm Meta‐Analysis and Systematic Review},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.15159}
}
EUVIMED